Clinical Trials Logo

Hemoperfusion clinical trials

View clinical trials related to Hemoperfusion.

Filter by:
  • None
  • Page 1

NCT ID: NCT05044403 Not yet recruiting - Sepsis Clinical Trials

Evaluation of the Efficacy and Safety of Extracorporeal Support With Hemoperfusion in Critical Patients With Multiorgan Dysfunction Syndrome by Septic Origin

Start date: October 1, 2021
Phase: Phase 4
Study type: Interventional

Low-level interventional clinical trial to evaluate the effectiveness and safety of extracorporeal support with hemoperfusion in critical patients with multiorgan dysfunction syndrome by septic origin.

NCT ID: NCT04643639 Completed - Sepsis Clinical Trials

Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis

EndoSorb
Start date: September 16, 2020
Phase: Phase 3
Study type: Interventional

In this randomized, open-label study, the investigators will assess whether CytoSorb hemoperfusion will prevent or attenuate the development of immunoparalysis in healthy volunteers undergoing repeated experimental endotoxemia.

NCT ID: NCT03487146 Completed - Hemoperfusion Clinical Trials

HP Improves Sleep and Overall Survival Rate in Maintenance Hemodialysis Patients

Start date: May 1, 2015
Phase: N/A
Study type: Interventional

Sleep disturbance has been long-standing torments in most of patients with maintenance hemodialysis (HD). In this study, we attempted to explore whether long-term hemoperfusion (HP) could improve sleep disorder and increase overall survival rate in HD patients.

NCT ID: NCT02461953 Completed - Quality of Life Clinical Trials

Combination of Hemodialysis With Hemoperfusion:A Clinical Study

Start date: June 2015
Phase: N/A
Study type: Interventional

This study is a prospective, randomized, controlled multicenter clinical study. The aim of the study is to investigate whether the combination of maintenance hemodialysis (MHD) with hemoperfusion (HP) could improve the clearance rate of middle and large molecule uremic toxins so as to improve the quality of life of MHD patients and reduce their mortality rate.